TRCT
CELZ icon

Tower Research Capital (TRC)’s Creative Medical Technology CELZ Stock Holding History

Tower Research Capital (TRC)’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.04K Buy
4,853
+2,761
+132% +$5.96K ﹤0.01% 4159
2026
Q1 		$4.31K Sell
2,092
-223
-10% -$436 ﹤0.01% 4209
2025
Q4 		$4.54K Buy
+2,315
New +$6.84K ﹤0.01% 4207
2025
Q3 		– Sell
-1,029
Closed -$2.73K – 5250
2025
Q2 		$2.73K Sell
1,029
-2,123
-67% -$4.57K ﹤0.01% 4602
2025
Q1 		$6.84K Buy
3,152
+1,504
+91% +$5.25K ﹤0.01% 4004
2024
Q4 		$3.81K Buy
1,648
+245
+17% +$740 ﹤0.01% 4588
2024
Q3 		$4.35K Sell
1,403
-696
-33% -$2.36K ﹤0.01% 4577
2024
Q2 		$8.08K Buy
2,099
+415
+25% +$1.88K ﹤0.01% 4399
2024
Q1 		$8.77K Buy
1,684
+781
+86% +$3.63K ﹤0.01% 3965
2023
Q4 		$4.16K Sell
903
-521
-37% -$2.38K ﹤0.01% 4987
2023
Q3 		$7.01K Sell
1,424
-629
-31% -$3.21K ﹤0.01% 4521
2023
Q2 		$9.52K Buy
2,053
+1,130
+122% +$6.55K ﹤0.01% 4269
2023
Q1 		$5K Hold
923
– – ﹤0.01% 4939
2022
Q4 		$4K Sell
923
-26
-3% -$107 ﹤0.01% 4988
2022
Q3 		$4K Sell
949
-6
-0.6% -$41 ﹤0.01% 5232
2022
Q2 		$7K Buy
955
+251
+36% +$4.05K ﹤0.01% 4767
2022
Q1 		$28K Buy
+704
New +$15.7K ﹤0.01% 3214

Other funds holding CELZ

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tower Research Capital (TRC)'s CELZ Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Creative Medical Technology (CELZ) stake by 132% in Q2 2026, buying an estimated $5.96K and bringing the position to 4,853 shares worth $7.04K. The position accounts for ﹤0.01% of the portfolio, ranked #4159.

Tower Research Capital (TRC) first reported a position in CELZ in Q1 2022 and has held it in 17 quarters since. The position peaked at $28K in Q1 2022. 15 funds tracked by Wall St. Rank hold CELZ as of Q2 2026.

  • Tower Research Capital (TRC) held 4,853 shares of Creative Medical Technology worth $7.04K as of Q2 2026.
  • Tower Research Capital (TRC) bought 2,761 Creative Medical Technology shares in Q2 2026, an estimated $5.96K.
  • Creative Medical Technology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4159 holding.
  • Tower Research Capital (TRC) first reported a position in Creative Medical Technology in Q1 2022 and has held it in 17 quarters since.
  • Tower Research Capital (TRC)'s Creative Medical Technology position peaked at $28K in Q1 2022.
  • 15 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.